By Tom Winnifrith | Thursday 29 August 2019
Disclosure: Financial Investigative Media Limited, which is not owned by Tom Winnifrith but by a trust for his dependants, owns shares in companies mentioned in this article. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
Shares in Optibiotix (OPTI) have fallen by more than a quarter on the back on results for the six months to May 31 which are, let us not kid ourselves, really not very impressive indeed. The bears are cock-a-hoop but now talking errant nonsense. We bulls look a bit daft. As a shareholder I feel a bit sore but, having chatted to CEO Steve O’Hara at length, I retain a stance of strong buy. I see one director, Fred Narbel, has bought 17,000 shares at 50p and I expect more, larger scale, boardroom buying to follow. And this is why...
Already a subscriber? Click here to sign in
This area of the ShareProphets.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ShareProphets.com. ShareProphets.com does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ShareProphets.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ShareProphets.com and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.
Search ShareProphets |
Stock market news |
Recent Comments |
Site by Everywhen